Evaluate the Serum of Irisin, Omentin-1, and Oxidative Status in Males with Prostatic Cancer

Abstract

Background:Prostate cancer is a classic public health problem in males and has broadly different levels of mortality and morbidity. As an endocrine gland, adipose tissue synthesizes and secretes a variety of bioactive peptides, such as irisin and omentin-1. Adipokines and oxidative stress potentially contribute to the proliferation of prostatic carcinoma cells. The relationship between irisin, omentin-1, and oxidative stress has not been widely investigated in prostate cancer. Therefore, the present research assessed whether there is a significant correlation between irisin and omentin-1 levels and oxidative status in prostate cancer individuals. Methods: The present research recruited 40 individuals diagnosed with prostate cancer and 40 healthy individuals for comparative purposes. All individuals underwent demographics, biochemicals, and serum adipokines (irisin and omentin-1) data analysis. Results: The means of total prostate-specific antigen (43.3±20.5 vs. 2.5±1.2) and free prostate-specific antigen (2.1±1.4 vs. 0.08±0.02) were highly significant increases in the prostate cancer patients than in the healthy individuals. Furthermore, the means of omentin-1 (31.6±12.8 vs. 23.5±14.1) and total oxidant stress (22.4±10.6 vs. 9.1±3.6) were highly significant increases in patients with prostate cancer than in healthy individuals. In contrast, the means of irisin (343.5±240.2 vs. 716.4±142.3) and total antioxidant capacity (2.2±1.2 vs. 3.3±1.3) were highly significant decreases in patients with prostate cancer than in healthy individuals. No significant relationship was demonstrated between all parameters in the two groups under study. Conclusion: The study findings indicate that irisin and omentin-1 could serve as biomarkers for predicting prostate cancer.